A healthcare company trying to launch a new headache curing drug. Should or shouldn't they invest when they already have a general painkiller in the market
Back to overview
18
How would I approach this? Possible Framework?
2
4.3k
Be the first to answer!
Nobody has responded to this question yet.
Top answer
Vlad
edited on Jun 05, 2018
Coach
McKinsey / Accenture Alum / Got all BIG3 offers / Harvard Business School
Hi,
Hi,
I recommend starting with clarifying the objective - Which metrics you need to achieve with the product? Most probably it will be ROI.
I would also clarify whether it's our painkiller on the market or the product of the competitors since competition and cannibalization are the two different cases. Then I will follow up with the structure:
Analyze our product:
- The value proposition of a product compared to the painkiller
- Different use cases of a product compared to the painkiller
- Unit economics (Current unit costs and costs in relation to scale, Investments, ROI targets, Competitor / substitutes pricing)
- Key capabilities to compete (Patent, distribution, etc)
Analyze the market:
- Size and growth rates of the painkiller market
- Size and growth rate of headache drugs
- Regulation - are they both OTC? Prescribed? Is it different by geography?
Analyze the competitors:
- Market shares, growth rates, profits
- Product (Value proposition)
- Unit economics (Value proposition vs. price vs. costs)
- Key capabilities (Distribution, supply, assets, knowledge, etc)
investment decision:
- Costs, benefits, and investments
- ROI
- Risks
Best!
0 comments
Sidi
on Jun 05, 2018
Coach
McKinsey Senior EM & BCG Consultant | Interviewer at McK & BCG for 7 years | Coached 500+ candidates secure MBB offers
Hi Anonymous,
the new drug should be launched if the net value associated with this move exceeds the investment cost over the client's target investment horizon. Morover, Risk needs to be manageable.
So you have 4 buckets to investigate:
- Net value (expected profits of new drug + impact on profits of current painkiller (potential cannibalization!))
- Investment Horizon
- Investment need for launch of the new drug
- Wider risks associated with the new drug (regulation? competitive responses? consumer sentiment?...)
Cheers, Sidi
Sign up for free to read all answers.
Sign up for free to read all answers.
Similar Questions
Most Popular Posts
Boomeranging to consulting after short late-stage startup stint - bad look for MBA?
9
on Jan 12, 2026
USA
8
100+
Top answer by
Evelina
Coach
EY-Parthenon l BCG offer l Revolut Problem Solving and Bar Raiser
8 Answers
100+ Views
+5
How can a mid-career professional transition into strategy consulting via part-time projects, shadowing, or internships?
9
on Jan 12, 2026
Global
10
200+
Top answer by
Melike
Coach
First session free | Ex-McKinsey | Break into MBB | Empowering you to approach interviews with clarity & confidence
10 Answers
200+ Views
+7
Is there a limit to the number of positions you can apply for at consulting firms?
9
on Jan 12, 2026
USA
6
200+
Top answer by
Evelina
Coach
EY-Parthenon l BCG offer l Revolut Problem Solving and Bar Raiser
6 Answers
200+ Views
+3
Questions after case: What to ask the interviewer
9
on Jan 15, 2026
Global
10
100+
Top answer by
Tyler
Coach
BCG interviewer | Ex-Accenture Strategy | 6+ years in consulting | Coached many successful candidates in Asia
10 Answers
100+ Views
+7
McKinsey JA role (london)
10
on Jan 16, 2026
UK
9
100+
Top answer by
Tommy
Coach
Ex-McKinsey associate and F500 director, experienced coach and mentor
9 Answers
100+ Views
+6